Effect of captopril and enalapril on endothelial function in hypertensive patients

M A Creager1, M A Roddy

  • 1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. 02115.

Insights

Essential hypertension impairs blood vessel dilation. Angiotensin-converting enzyme inhibitors like captopril and enalapril improved vasodilation in hypertensive patients, with no significant difference between the two drugs.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Endothelium-dependent vasodilation is reduced in patients with essential hypertension.
  • Nitric oxide plays a role in vasodilation, and tissue thiols may influence this process.

Purpose of the Study:

  • To investigate if long-term angiotensin-converting enzyme inhibitor (ACE inhibitor) treatment improves endothelium-dependent vasodilation in hypertensive patients.
  • To determine if an ACE inhibitor with a sulfhydryl group (captopril) offers preferential benefits over one without (enalapril) for vasodilation.

Main Methods:

  • 24 hypertensive patients and 20 normotensive controls were studied.
  • Forearm resistance vessel vasodilation was assessed using methacholine chloride infusion.
  • Endothelium-independent vasodilation was evaluated with nitroglycerin.
  • Forearm blood flow was measured using plethysmography.
  • Hypertensive patients were treated with either captopril or enalapril for 7-8 weeks.

Main Results:

  • Hypertensive patients showed impaired vasodilation to methacholine compared to normotensive subjects before treatment (P < .01).
  • Nitroglycerin's effects on forearm blood flow were similar between groups.
  • Both captopril and enalapril effectively reduced blood pressure in hypertensive patients.
  • The study abstract was truncated, preventing full reporting of results regarding differential effects of captopril vs. enalapril on vasodilation.

Conclusions:

  • Essential hypertension is associated with impaired endothelium-dependent vasodilation.
  • ACE inhibitors, including captopril and enalapril, can improve blood pressure in hypertensive individuals.
  • Further research is needed to fully elucidate the differential effects of sulfhydryl-containing ACE inhibitors on vasodilation.

Related Concept Videos

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...